Selvita registered charter changes. Selvita stock fell 2.69 percent

Published on 10/08/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Selvita reported first-half sales of PLN 158.10 million versus PLN 183.76 million. Selvita stock costs EUR 5.06 after EUR 5.20 on October 8, 2026.

Selvita, PLSLVCR00029, Illustration mit AI erstellt.

Selvita stock (PLSLVCR00029) was trading at EUR 5.06 at Lang & Schwarz on October 8, 2026 at 12:41 p.m. CEST, down 2.69 percent from the prior close of EUR 5.20. The company had registered an administrative amendment to its articles of association on October 2, 2026, according to Parkiet.

Charter change stays administrative

The amendment aligned the business activity codes and descriptions in Selvita's articles with Poland's PKD 2025 classification. The filing said the change did not materially expand or restrict the company's business activities.

For investors, the filing is a governance update rather than a change to Selvita's operating scope. The more important operating question remains the balance between its two core activities, drug discovery and drug development.

First-half sales fell 14.00 percent

MarketScreener reported on September 16, 2026 that sales for the six months ended June 30, 2026 fell to PLN 158.10 million from PLN 183.76 million a year earlier, a 13.96 percent decline.

The same report showed a PLN 8.49 million net loss for the first half of 2026, compared with a PLN 5.60 million loss in the first half of 2025. That deterioration makes revenue quality and cost control more important than the statutory sales figure alone.

Drug development offers contrast

Selvita's first-half 2026 results also showed a sharp split between business lines. Commercial revenue in Drug Development reached PLN 55.30 million, up 16.00 percent year over year, while the segment's EBITDA reached PLN 16.10 million, up 26.00 percent, according to Strefa Inwestorow. The group's backlog for 2026 stood at PLN 306.00 million versus PLN 334.00 million a year earlier.

The contrast points to execution risk concentrated in Drug Discovery, while the faster-growing Drug Development segment provides a measurable counterweight. Selvita also appointed Rafa? Chwast as chief executive in the first-half update, adding a management transition to the operating story.

Stock trades below prior close

At Lang & Schwarz, Selvita stock was trading at EUR 5.06 on October 8, 2026 at 12:41 p.m. CEST, down 2.69 percent versus the Lang & Schwarz prior close of EUR 5.20 on October 7, 2026. The primary Warsaw Stock Exchange quote was PLN 22.10 at 10:31 a.m. UTC on October 8, 2026, while the 52-week range was PLN 20.20 to PLN 49.40 and market capitalization was PLN 405.6 million.

The further course of trading is shown by the continuously updated real-time quote of Selvita stock.